In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioSpace
BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model – called XSeed Labs – entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
Wall Street Online
BioMed X announced today the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs. The first research project of the new lab will focus on fibrotic disease processes, a key focus area of Boehringer Ingelheim.
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
Yahoo! Finance
BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model launched today – called XSeed Labs – entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.
Visit: BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
Access Wire
BioMed X announced today the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs. The first research project of the new lab will focus on wound healing & fibrosis.
Visit: BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
Open PR
Nach dem erfolgreichen Abschluss eines RNA-Splicing-Projekts in der Tumorforschung im Januar dieses Jahres setzen BioMed X und Merck ihre Zusammenarbeit im Bereich der Onkologie fort, um nach Möglichkeiten der Verstärkung der Tumorimmunogenität zu suchen.
Visit: BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
PharmiWeb
After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.
Visit: BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
Access Wire
After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.
Visit: BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
BioMed X and Merck erweitern Zusammenarbeit mit dem Ziel der Nutzung von krebsspezifischen Vulnerabilitäten für zielgerichtete Therapien
Finanz Nachrichten
Nach dem erfolgreichen Abschluss eines RNA-Splicing-Projekts in der Tumorforschung im Januar dieses Jahres setzen BioMed X und Merck ihre Zusammenarbeit im Bereich der Onkologie fort, um nach Möglichkeiten der Verstärkung der Tumorimmunogenität zu suchen.
Visit: BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
Yahoo! Finance
BioMed X, an independent biomedical research institute, announces the start of its new research project – “New Strategies to Enhance the Immunogenicity of Tumors” – in collaboration with Merck. The focus of this new research group will be to develop novel approaches for enhancing tumor immunogenicity to broaden the population of patients who could benefit from cancer immunotherapy.
Visit: BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
BioSpace
After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.